Related Experiment Video
Updated: Jan 6, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
14.3K
Individualizing Thromboprophylaxis: From Fixed Doses to Targeted Low-Molecular-Weight Heparin Use.
Ourania S Kotsiou1,2, Dimos Charalampidis3, Konstantinos N Malizos4
1Laboratory of Human Pathophysiology, School of Health Sciences, Department of Nursing, University of Thessaly, Larissa, Greece. raniakotsiou@gmail.com.
Cardiovascular Drugs and Therapy
|November 13, 2025
Summary
Individualized low-molecular-weight heparin (LMWH) dosing guided by anti-factor Xa (anti-Xa) levels can improve venous thromboembolism (VTE) prophylaxis. Anti-Xa monitoring optimizes LMWH therapy, especially in high-risk patients, but requires further standardization.
Area of Science:
- Pharmacology
- Thrombosis Research
- Clinical Medicine
Background:
- Venous thromboembolism (VTE) is a major cause of postoperative complications.
- Standard low-molecular-weight heparin (LMWH) dosing often fails to achieve therapeutic anti-factor Xa (anti-Xa) levels.
- Patient-specific factors necessitate personalized anticoagulant strategies.
Purpose of the Study:
- To review evidence on individualized LMWH thromboprophylaxis using anti-Xa-guided dosing.
- To assess the clinical effectiveness and implementation challenges of anti-Xa-guided LMWH.
- To evaluate LMWH efficacy across various patient settings.
Main Methods:
- Systematic literature review.
- Inclusion of studies on fixed-dose, weight-based, and anti-Xa-adjusted LMWH.
- Analysis across trauma, surgical, intensive care, and oncology patient cohorts.
Main Results:
- Subtherapeutic anti-Xa levels observed in up to 87.7% of patients on fixed-dose LMWH.
- Anti-Xa-guided dosing improved prophylactic level attainment and reduced VTE incidence.
- No significant increase in major bleeding events with adjusted dosing.
- Study design heterogeneity and small sample sizes limit adoption.
Conclusions:
- Individualized LMWH dosing via anti-Xa monitoring shows promise for selected patients.
- Standardized testing and prospective validation are crucial for clinical implementation.
- Anti-Xa-guided therapy offers a personalized approach to VTE prevention.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
01:29Venous Thrombosis III: Interprofessional Care
254
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
254
01:24Dosage Regimen: Individualization
146
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
146
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
185
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
185